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Type 3 deiodinase (D3) inactivates thyroid hormones. Simonides et al. (2008) now report that hypoxia-
induced D3 activation leads to reduction of 3,5,30-triiodothyronine (T3) and oxygen consumption, suggesting
that D3 activation is a component of cellular responses to hypoxia and supporting the idea of cell-specific
regulation of thyroid hormone levels by deiodinases.Thyroid hormone is a critical regulator of
cell functions during development and in
adulthood. The main secretory product
of the thyroid gland is thyroxine (T4).
Once in the target tissues, T4 can be
either converted to its active form, 3,5,
30-triiodothyronine (T3), or inactivated to
reverse T3 (rT3) by a process called deio-
dination. Three enzymes have been char-
acterized that are responsible for the
deiodination of thyroid hormones. Type
1 deiodinase (D1) is present in many adult
tissues including kidney, liver, and thyroid
gland, where it is responsible for both
phenolic and tyrosyl ring deiodination of
thyroid hormones. Type 2 deiodinase
(D2) is mostly expressed in brain, pitui-
tary, brown adipose tissue, and placenta.
It only catalyzes the phenolic ring deiodi-
nation converting T4 to T3 and thus is
considered the main enzyme responsible
for thyroid hormone action. Finally, type
3 deiodinase (D3) is highly expressed in
placenta and in several fetal tissues. Post-
natally, D3 remains expressed in the brain
and skin, where it specifically catalyzes
tyrosyl ring deiodination, thus inducing
the inactivation of thyroid hormones (for
review, seeBianco et al., 2002). In a recent
issue of The Journal of Clinical Investiga-
tion, Simonides et al. (2008) report that
D3 plays a role in cellular metabolism dur-
ing hypoxic-ischemic disease by inacti-
vating thyroid hormone. Using a rat model
of cardiac failure, the authors showed
both in vitro and in vivo that D3 activation
induces cell-specific reduction of T3
content and oxygen consumption. These
observations suggest that D3 activation
is a component of metabolic regulation
during ischemic events and further
strengthen the idea that cell-specific reg-ulation of thyroid hormone levels by deio-
dinases plays a role in cell metabolism.
Modulation of the deiodinases occurs
in a tissue-specific manner. For example,
during neutral energy balance, thyroid
hormone levels are important regulators
of D2 activity, whereas when energy
levels are low, D2 regulation is uncoupled
from thyroid regulation: D2 activity is up-
regulated in the hypothalamic glial cells
(tanycytes) during fasting, an event that
is independent of circulating T4 levels
(Diano et al., 1998; Coppola et al., 2005).
Under these circumstances, D2 increases
hypothalamic T3 levels, resulting in tissue
hyperthyroidism despite systemic hypo-
thyroidism (Coppola et al., 2007). This
shift in thyroid hormone availability has
an impact on appropriate neuronal and
behavioral responses to fasting such as
the activation of arcuate nucleus neuronal
circuits and feeding (Coppola et al., 2007).
Similar to tissue-specific regulation of
D2, Simonides et al. (2008) describe cell-
specific modulation of D3 during hyp-
oxic-ischemic events. In contrast to D2
activation, which promotes cell metabo-
lism, the authors show that upregulation
of D3 activity is an important mechanism
during hypoxia to decrease T3-depen-
dent oxygen consumption. Using cell
lines endogenously expressing D3, Simo-
nides and collaborators show that D3
activity is enhanced by hypoxia via a
hypoxia-inducible factor (HIF)-dependent
pathway. The increased D3 activity may
lead to reduced cellular T3 levels, which
in turn reduce oxygen consumption, thus
decreasing cellular metabolism. In agree-
ment with the in vitro studies, the authors
also show that in a rat model of cardiac
failure due to right ventricle hypertrophy,Cell MetabD3 activity levels increase while tissue
T3 levels decrease. In light of the findings
of Simonides et al. and earlier observa-
tions of tissue-specific deiodinase mod-
ulation, it is plausible to conclude that
tissue T3 formation and degradation by
deiodinases play a role in the regulation
of cell metabolism during cellular stress.
While Simonides et al. (2008) provide an
elegant set of in vitro and in vivo studies to
reveal the involvement of D3 in the cellular
response to hypoxia, the overall signifi-
cance of D3 activation in cell, tissue, and
organism survival in the short and long
term remains to be elucidated. Whether
the viability of the cells exposed to hyp-
oxia is affected by D3 activation, and
thus hypothyroid conditions, has not
been assessed and represents an impor-
tant next step. D3-triggered decreases in
oxygen consumption that may lower tem-
perature in the affected region due to cel-
lular hypothyroidism of the injured cells
could lead to various outcomes regarding
cell and tissue survival after hypoxia
(Figure 1). Shutting off or dramatically de-
creasing oxygen consumption could lead
to the collapse of mitochondrial energy
homeostasis, resulting in cell death. While
this event could aid the appropriate func-
tioning of nonaffected cells as the authors
suggest, a degenerative process would
also activate mechanisms that can lead
to local and general inflammation. On
the other hand, a partial reduction in oxy-
gen consumption could also lead to amet-
abolic state with less generation of reac-
tive oxygen species that allows repair
mechanisms to emerge to rescue the
affected cell. This mechanism would
also show inflammatory characteristics,
at least during the process of activeolism 7, May 2008 ª2008 Elsevier Inc. 363
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ever, may promote acute survival of the
tissue as long as the hypoxic event is focal
and not global and as long as it does not
occur in subsets of cells that are critical
for organism survival. On the other hand,
the described effects of D3 on the cellular
machinery of fuel utilization may have un-
desired consequences during the time of
reperfusion. Indeed, a great part of the
detrimental effects induced by acute hyp-
oxia-ischemia are due to subsequent
reperfusion of the tissue with norm- or
hyperoxygenated blood. The findings re-
ported by Simonides et al. may actually
explain why reperfusion could be detri-
mental: as the cellular machinery of fuel
utilization is diminished by D3 in response
to hypoxia, during the course of reperfu-
sion, the generation of damaging oxygen
free radicals will be increased.
It will be important to assess what de-
termines the levels of D3 induction by
hypoxia. One intriguing possibility is that
a significant determinant might be the re-
lationship between the level of and expo-
sure to hypoxia and the metabolic condi-
tion of the cell, with particular emphasis
on the state of mitochondrial bioenerget-
ics, at the time of the hypoxic insult. A
related and important question also re-
mains: What is the molecular mediator of
hypoxia-induced induction of HIF1, which
in turn promotes D3 transcription? For
example, if a cardiac myocyte, neuron,
or hepatocyte is in a better mitochondrial
bioenergetic state than another cell with
a similar level of oxygen consumption,
Figure 1. D3 Activation during Hypoxia
Schematic illustration of the possible effects of D3 activation during hypoxic events. Hypoxia-induced
HIF1 activation triggers D3 upregulation, which in turn reduces cellular T3 levels andmitochondrial oxygen
consumption (green mitochondria indicate normal oxygen consumption; red mitochondria indicate low
oxygen consumption). Purple cells (representing cardiomyocytes, neurons, or hepatocytes) indicate nor-
moxic conditions; blue cells indicate hypoxic conditions. The outcome of D3 induction may lead to either
degeneration or regeneration of cells. The overall effect of hypoxia on D3 induction may depend on the
metabolic status of the cells at the time of the hypoxic insult. For example, cells with enhanced mitochon-
drial bioenergetics due to UCP2 (a protein whose expression and activity can be enhanced by D2) may
respond to a hypoxic insult with altered D3 expression compared to a cell with lower mitochondrial bio-
energetic characteristics.364 Cell Metabolism 7, May 2008 ª2008 Elsevier Inc.would a hypoxic event induce altered
induction of HIF1 and consequent D3
levels? In this regard, it is noteworthy to
mention that preconditioning and mito-
chondrial proliferation have been tied to
the activation ofmitochondrial uncoupling
protein 2 (UCP2). Interestingly, UCP2
transcription and activity are positively
regulated by another deiodinase enzyme,
D2 (Coppola et al., 2007). UCP2, which is
also expressed in the heart (Lanni et al.,
1997), promotes neuronal survival during
various experimental cellular stress para-
digms, including models of epilepsy, Par-
kinson’s disease, and focal and global
ischemia models (Andrews et al., 2005;
Deierborg Olsson et al., 2008) as well as
oxidative stress in cardiomyocytes (Te-
shima et al., 2003). It is therefore tempting
to speculate that both D2 and D3 may
play critical and interrelated roles at differ-
ent stages of cellular damage by affecting
metabolic activity and survival.
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